CD44v6 is not a prognostic factor in primary breast cancer

Annals of Oncology

Volumn 9, Issue 1, 1998, Pages 109-111

  Jansen, R H L ^a   Joosten Achjanie, S R ^a   Arends, J W ^a   AVolovics, ^b   Hupperets, P S G J ^a   Schouten, H C ^a   Hillen, H F P ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

CD44v6; Primary breast cancer; Prognostic factor

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; HERMES ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031928853     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008220917687     Document Type: Article

References (15)

1. Sleeman J, Moll J, Sherman L et al. The role of CD44 splice variants in human metastatic cancer. Ciba Foundation Symp 1995; 189: 142-56.
2. Screaton GR, Bell MV, Jackson DG et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89: 12160-4.
3. Tölg C, Hofmann M, Herrlich P, Ponta H. Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res 1993; 21: 1225-9.
4. Günthert U, Hofmann M, Rudy W et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24.
5. Mulder JWR, Kruyt PM, Sewnath M et al. Colorectal cancer prognosis and expression of exon-V6-containing CD44 proteins. Lancet 1994; 344: 1470-2.
6. Kaufmann M, Heider KH, Sinn HP et al. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995; 345: 615-9.
7. Friedrichs K, Franke F, Lisboa BW et al. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 1995; 55: 5424-33.
8. Hupperets P, Wils J, Volovics L et al. Adjuvant hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients: Update at 7 years follow-up. Ann Oncol 1995; 6: 90-1.
9. Hupperets PS, Schutte B, Van Assche C et al. Ploidy and S-phase fractions (SPF) of primary breast cancer and their nodal metastases. Breast Cancer Res Treat 1994; 32: 197-202.
10. Friedrichs K, Kugler G, Franke F et al. CD44 isoforms in prognosis of breast cancer. Lancet 1995; 345: 1237 (Letter).
11. Schumacher U, Horny HP, Horst HA et al. A CD44 variant exon 6 epitope as a prognostic indicator in breast cancer. Eur J Surg Oncol 1996; 22: 259-61.
12. Tempfer C, Losch A, Heinzl H et al. Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer. Eur J Cancer 1996; 32A: 2023-5.
13. Regidor PA, Callies R, Regidor M et al. Expression of the CD44 variant isoforms 6 and 4/5 in breast cancer - correlation with established prognostic parameters. Arch Gynecol Obstet 1996; 258: 125-35.
14. Fox SB, Fawcett J. Jackson DG et al. Normal human tissues, in addition to some tumors, express multiple CD44 isoforms. Cancer Res 1994; 54: 4539-46.
15. Man-Sun S, Mori H, Liu D. CD44 as a marker in human cancer. Curr Opin Oncol 1997; 9: 108-12.